11.10.2006 – 09:01

/K I L L K I L L K I L L -- Bristol-Myers Squibb Medical Imaging/

Journalists and other readers should disregard the news release
"Bristol-Myers Squibb Medical Imaging Receives European Commission
Marketing Authorisation for Its Ultrasound Contrast Agent
LUMINITY(TM)  (perflutren lipid microsphere)" NYSE:BMY, issued
earlier today. The release  was issued prematurely by PR Newswire.

Contact:

Brian Henry, +33-1-58-83-69-38, brian.henry@bms.com, or Lili Gordon,
+1-617-733-7537, lili.gordon@bms.com, both of Bristol-Myers Squibb

Weitere Storys: Bristol-Myers Squibb Medical Imaging

Alle Storys Alle

11.10.2006 – 08:33
Bristol-Myers Squibb Medical Imaging Receives European Commission Marketing Authorisation for Its Ultrasound Contrast Agent LUMINITY(TM) (perflutren lipid microsphere)
N. Billerica, Massachusetts (ots/PRNewswire) - Bristol-Myers Squibb Medical Imaging announced today that the European Commission has granted marketing authorisation for LUMINITY(TM), an ultrasound contrast agent, for use in patients with suboptimal echocardiograms who have suspected or established ...
mehr

/K I L L K I L L K I L L -- Bristol-Myers Squibb Medical Imaging/

Economy

Health

Wirtschaft

Bristol-Myers Squibb Medical Imaging Receives European Commission Marketing Authorisation for Its Ultrasound Contrast Agent LUMINITY(TM) (perflutren lipid microsphere)